Inhibitors of cholesteryl ester transfer protein - a step forward in the treatment of coronary artery disease?

被引:0
|
作者
Doggrell, SA [1 ]
机构
[1] Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia
关键词
D O I
10.1358/dof.2005.030.01.870718
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although the LDL cholesterol-lowering statins have reduced the mortality and morbidity associated with coronary artery disease (CAD), considerable mortality and morbidity remains. Increasing HDL cholesterol levels is associated with reduced CAD mortality and morbidity. In healthy subjects with mild dyslipidemia, treatment with JTT-705 decreased cholesteryl ester transfer protein (CETP) activity, increased HDL cholesterol and decreased LDL cholesterol. Similarly, another CETP inhibitor, torcetrapib, has recently been shown to increase HDL cholesterol by 46%, decrease LDL cholesterol by 8% and have no effect on triglycerides in subjects with HDL cholesterol levels below 1.0 mmol/l. Increasing HDL cholesterol with inhibitors of CETP represents a new approach to dyslipidemia that requires further investigation, especially in patients with CAD.
引用
收藏
页码:45 / 50
页数:6
相关论文
共 50 条